The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review ; volume:14 ; number:1 ; day:27 ; month:12 ; year:2022 ; pages:1-15 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (27.12.2022), 1-15, 12.2022

Creator: Brand, Abby L.
Lawler, Paige E.
Bollinger, James G.
Li, Yan
Schindler, Suzanne E.
Li, Melody
Lopez, Samir
Ovod, Vitaliy
Nakamura, Akinori
Shaw, Leslie M.
Zetterberg, Henrik
Hansson, Oskar
Bateman, Randall J.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-022-01117-1

URN: urn:nbn:de:101:1-2023030821133749679340

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:00 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Brand, Abby L.
Lawler, Paige E.
Bollinger, James G.
Li, Yan
Schindler, Suzanne E.
Li, Melody
Lopez, Samir
Ovod, Vitaliy
Nakamura, Akinori
Shaw, Leslie M.
Zetterberg, Henrik
Hansson, Oskar
Bateman, Randall J.
SpringerLink (Online service)

Other Objects (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

Amyloid blood biomarker detects Alzheimer's disease

Blood-based molecular biomarkers for Alzheimer’s disease

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease

Related objects

Reset password